Related references
Note: Only part of the references are listed.In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth
Maxwell J. Lasko et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2022)
Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update
Emily N. Drwiega et al.
CLINICAL PHARMACOKINETICS (2022)
Emergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan
Rui-Xin Wu et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2022)
Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals
Sadia H. Sarzynski et al.
OPEN FORUM INFECTIOUS DISEASES (2022)
Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy
Samuel L. Aitken et al.
CLINICAL INFECTIOUS DISEASES (2021)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
Effect of antimicrobials on Stenotrophomonas maltophilia biofilm
Barbara Ellen Santos Carvalhais et al.
FUTURE MICROBIOLOGY (2021)
Optimization of Aztreonam in Combination With Ceftazidime/Avibactam in a Cystic Fibrosis Patient With Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring: A Case Study
Mallory C. Cowart et al.
THERAPEUTIC DRUG MONITORING (2021)
In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia
Rio Nakamura et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia
Ayesha Khan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
StenoSCORE: Predicting Stenotrophomonas maltophilia Bloodstream Infections in the Hematologic Malignancy Population
Sara M. Karaba et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Advances in the Microbiology of Stenotrophomonas maltophilia
Joanna S. Brooke
CLINICAL MICROBIOLOGY REVIEWS (2021)
Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy *
Shauna Jacobson Junco et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo murine infection models
Christian M. Gill et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies
Daniel D. Rhoads
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia
Ayesha Khan et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
Tigecycline in the Treatment of Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia: A Multicenter Retrospective Cohort Study
Lei Zha et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Successful use of avibactam and aztreonam combination for a multiresistant Stenotrophomonas maltophilia bloodstream infection in a patient with idiopathic medullary aplasia
A. Diarra et al.
INFECTIOUS DISEASES NOW (2021)
Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically III Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)
Thomas P. Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole
M. Biagi et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge
Teresa Gil-Gil et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia
Mercedes Delgado-Valverde et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia
Matthias I. Groeschel et al.
NATURE COMMUNICATIONS (2020)
The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study
Bin Cai et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia
M. Biagi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Minocycline Intravenous for the Treatment of Serious Infections Due to Gram-Negative Nonpseudomonal Bacteria, IncludingStenotrophomonas maltophilia,Acinetobacter baumannii, andBurkholderia cepacia
Miguel Sierra-Hoffman et al.
INFECTIOUS DISEASES IN CLINICAL PRACTICE (2020)
Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria
Cecile Emeraud et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016)
Ana C. Gales et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia
Megan D. Shah et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Treatment Outcomes of Stenotrophomonas maltophilia Bacteremia in Critically Ill Children: A Multicenter Experience
Itay Tokatly Latzer et al.
PEDIATRIC CRITICAL CARE MEDICINE (2019)
In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models
Rio Nakamura et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States
Maria F. Mojica et al.
MBIO (2019)
In Vitro Activity of Minocycline against US Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018
Robert K. Flamm et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections
Cara Nys et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model
Iris H. Chen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis
J-H. Ko et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study
Philippe Guerci et al.
CRITICAL CARE (2019)
Implementation and optimization of molecular rapid diagnostic tests for bloodstream infections
Eric Wenzler et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2018)
Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections
Lucas Watson et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2018)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints
April M. Bobenchik et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2017)
Comparison of Monotherapy Versus Combination Therapy for Stenotrophomonas maltophilia Pneumonia Including Trimethoprim-Sulfamethoxazole-Containing and -Sparing Regimens
Patrick Lake et al.
Open Forum Infectious Diseases (2017)
Clinical Characteristics of Stenotrophomonas maltophilia Bacteremia: A Regional Report and a Review of a Japanese Case Series
Hirotaka Ebara et al.
INTERNAL MEDICINE (2017)
Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients
Hideki Araoka et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
Impacts of Penicillin Binding Protein 2 Inactivation on β-Lactamase Expression and Muropeptide Profile in Stenotrophomonas maltophilia
Yi-Wei Huang et al.
MSYSTEMS (2017)
Sensitivity Analysis in Observational Research: Introducing the E-Value
Tyler J. VanderWeele et al.
ANNALS OF INTERNAL MEDICINE (2017)
Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient
Maria F. Mojica et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Emerging Resistance, New Antimicrobial Agents ... but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape
R. M. Humphries et al.
CLINICAL INFECTIOUS DISEASES (2016)
Prevalence of Immunosuppression Among US Adults, 2013
Rafael Harpaz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections
Shauna Jacobson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections
Elizabeth Hand et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Relationship of Sulfamethoxazole Therapeutic Drug Monitoring to Clinical Efficacy and Toxicity: A Retrospective Cohort Study
Lauren L. Ice et al.
THERAPEUTIC DRUG MONITORING (2016)
Tetracycline Antibiotics and Resistance
Trudy H. Grossman
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments
Chuanqi Wei et al.
PLOS ONE (2016)
Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies
Antoine Grillon et al.
PLOS ONE (2016)
The Efflux Pump SmeDEF Contributes to Trimethoprim-Sulfamethoxazole Resistance in Stenotrophomonas maltophilia
Maria Blanca Sanchez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations
Sung-Yeon Cho et al.
BMC INFECTIOUS DISEASES (2015)
Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience
James A. McKinnell et al.
CLINICAL INFECTIOUS DISEASES (2015)
Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients
Nicholas S. Britt et al.
CLINICAL INFECTIOUS DISEASES (2015)
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
Ya-Ting Chang et al.
FRONTIERS IN MICROBIOLOGY (2015)
A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia
Chuanqi Wei et al.
INFECTIOUS DISEASES (2015)
Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia
Eleni P. Balli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Monotherapy with Fluoroquinolone or Trimethoprim-Sulfamethoxazole for Treatment of Stenotrophomonas maltophilia Infections
Yu Lin Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Can Levofloxacin Be a Useful Alternative to Trimethoprim- Sulfamethoxazole for Treating Stenotrophomonas maltophilia Bacteremia?
Sun Young Cho et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis
Yu-Chung Chuang et al.
BMC INFECTIOUS DISEASES (2014)
Interplay between intrinsic and acquired resistance to quinolones in Stenotrophomonas maltophilia
Guillermo Garcia-Leon et al.
ENVIRONMENTAL MICROBIOLOGY (2014)
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012
Helio S. Sader et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Cotrimoxazole - optimal dosing in the critically ill
Glen R. Brown
ANNALS OF INTENSIVE CARE (2014)
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria
Gennaro De Pascale et al.
CRITICAL CARE (2014)
Systematic Review and Meta-Analysis of Linezolid and Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bloodstream Infections
Donald W. Whang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia
Julio Ramirez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Pranita D. Tamma et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Joanna S. Brooke
CLINICAL MICROBIOLOGY REVIEWS (2012)
Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections
Yasemin Tezer Tekce et al.
JOURNAL OF CHEMOTHERAPY (2012)
Stenotrophomonas maltophilia Infections in a General Hospital: Patient Characteristics, Antimicrobial Susceptibility, and Treatment Outcome
George Samonis et al.
PLOS ONE (2012)
Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus
Sandrine Lemaire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron
Li-Fen Hu et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Clinical and Microbiologic Outcomes in Trauma Patients Treated for Stenotrophomonas maltophilia Ventilator-Associated Pneumonia
Quinn A. Czosnowski et al.
PHARMACOTHERAPY (2011)
Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Ronald N. Jones
CLINICAL INFECTIOUS DISEASES (2010)
Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature
Matthew E. Falagas et al.
FUTURE MICROBIOLOGY (2009)
The versatility and adaptation of bacteria from the genus Stenotrophomonas
Robert P. Ryan et al.
NATURE REVIEWS MICROBIOLOGY (2009)
Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants
Maria B. Sanchez et al.
BMC MICROBIOLOGY (2008)
Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole:: a systematic review
Matthew E. Falagas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants
Lisa C. Crossman et al.
GENOME BIOLOGY (2008)
Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the united states between 1993 and 2004
Shawn R. Lockhart et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia
Valerie J. Waters et al.
INFECTION AND IMMUNITY (2007)
Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004
G. Aisenberg et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2007)
Social work admission assessment tool for identifying patients in need of comprehensive social work evaluation
C Boutin-Foster et al.
HEALTH & SOCIAL WORK (2005)
Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia
SA Zelenitsky et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia
GL Drusano et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model
BB Ba et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Innate host Defense of the lung: Effects of lung-lining fluid pH
AW Ng et al.
LUNG (2004)
Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis
P San Gabriel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces
D de Oliveira-Garcia et al.
CELLULAR MICROBIOLOGY (2003)
Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)
DJ Hoban et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2003)
Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates
A Ribera et al.
MICROBIAL DRUG RESISTANCE (2002)
Evaluation of the VITEK 2 system for the identification and susceptibility testing of three species of nonfermenting gram-negative rods frequently isolated from clinical samples
P Joyanes et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia
A Alonso et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia
K Weiss et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria
K Poole
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
